Safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WBP216, a novel IL-6 monoclonal antibody, in patients with rheumatoid arthritis: A phase Ia randomized placebo-controlled study

BACKGROUND: WBP216 is a novel human immunoglobulin G1 (IgG1) monoclonal antibody for interleukin (IL)-6. We aimed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single ascending dose (SAD) of WBP216 in patients with rheumatoid arthritis (RA). METHODS: In th...

Descripción completa

Detalles Bibliográficos
Autores principales: Leng, Xiaomei, Tang, Xiange, Hu, Pei, Guan, Xiaoduo, Li, Qian, Huang, Cipo, Zhang, Qiang, Chen, Rui, Zeng, Xiaofeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011485/
https://www.ncbi.nlm.nih.gov/pubmed/36926529
http://dx.doi.org/10.3389/fimmu.2022.1110992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011485/
https://www.ncbi.nlm.nih.gov/pubmed/36926529
http://dx.doi.org/10.3389/fimmu.2022.1110992

Ejemplares similares